Press Resease

Human insulin Market - Global Industry Analysis

Human insulin Market by Product (Drugs and Drug Delivery Devices), By Application (Insulin dependent diabetes mellitus (Type 1) and Non-Insulin dependent diabetes mellitus (Type 2)): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2028

Published Date: 29-Jul-2021 Category: Healthcare Report Format : PDF Pages: 180 Report Code: ZMR-101 Status : Published

The global Human insulin market accounted for USD 33.7 Billion in 2020 and is expected to reach USD 68 Billion by 2028, growing at a CAGR of around 8.9% between 2021 and 2028.

Description

Market Overview     

The global Human insulin market accounted for USD 33.7 Billion in 2020 and is expected to reach USD 68 Billion by 2028, growing at a CAGR of around 8.9% between 2021 and 2028.      

Human insulin is the term that describes synthetic insulin which is grown in a laboratory to mimic the insulin in humans. In a laboratory, it is created by growing insulin proteins within E-coli bacteria (Escherichia coli). It is mainly available in two forms, a short acting (regular) form and an intermediate acting (NPH) form. Human insulin was developed as an insulin that could be created in large amounts at a relatively low cost. It can be administered orally or through insulin infusion devices. Some conventional insulin infusion devices are syringes, insulin pumps, and injection pens. These devices are used to deliver insulin on time and regularly.

COVID-19 Impact Analysis  

The global human insulin market has witnessed a slight decline in the sales for short term to the lockdown enforcement placed by governments in order to contain COVID spreading. The restrictions imposed by various nations to contain COVID had stopped the production resulting in a disruption across the whole supply chain. However, the global markets are slowly opening to their full potential and theirs a surge in demand. The market would remain bullish in upcoming year.  Rising support from governments and several companies can help in the fight against this disease. Overall, almost every sector is anticipated to be impacted by the pandemic.

The significant decrease in the global Human insulin market size in 2020 is estimated on the basis of the COVID-19 outbreak and its negative impact on the economies and industries across the globe. Various scenarios have been analyzed on the basis of inputs from various secondary sources and the current data available about the situation.

Global Human insulin Market Size

Growth Factors

The global human insulin market is likely to see noteworthy development in the years to come. This development in global human insulin market is attributed owing to the rising market demand for human insulin analogs, increasing risk of diabetes, favorable medical reimbursements, and technological enactments in the field of human insulin delivery devices. An insulin routine is often needed in the treatment of gestational diabetes and diabetes related with specific syndromes or conditions (such as chemical or drug-induced diabetes, pancreatic diseases, insulin-receptor disorders, endocrinopathies, and specific genetic syndromes). In all cases of insulin employment, the dosage of insulin must be balanced and individualized with exercise and medical nutrition therapy, thereby boosting the global human insulin market.

Increasing technical advancements is also one of the reasons for the growth of the global human insulin market. For instance, in June 2018, Eli Lilly and Company’s Humulin R U-500 (that was used in insulin pumps) displayed greater A1C lowering in adults suffering from type 2 diabetes. This was compared extraordinary in comparison to MDI (multiple daily injections), thereby driving the growth of global human insulin market.

Report Scope:  

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Segment Analysis Preview  

Based on product, drugs were likely to add up for the biggest market share of the global human insulin market and are expected to stay the same in the near future. Requirement for biosimilar drugs is sturdy in both developing and developed nations owing to its low-cost therapy. This is boosted by the requirement for the best valuable therapy, which can frequently be expensive. Biosimilar insulin drug might provide a less-pricy option to current human insulin biologics, thus boosting the global human insulin market.

Regional Analysis Preview  

North America has been leading the worldwide human insulin market and is anticipated to continue on the dominant position in the years to come. The factors such as growing old age population, rising prevalence of diabetes, increasing healthcare awareness, improvement in reimbursement policies, and surge in clinical trials driving the growth of human insulin in North America.

Global Human insulin Market Share

Key Market Players & Competitive Landscape

Some of the major players of the global human insulin market include Eli Lilly, GlaxoSmithCline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, and Wockhardt among others.

Global Human insulin Market Regional Analysis

The global Human insulin Market is segmented as follows:

By Products

  • Drugs
    • Insulin Analogs and Biosimilars
    • Human Insulin Biologics
  • Drug Delivery Devices
    • Pens
    • Pen Needles
    • Syringes

By Applications

  • Insulin dependent diabetes mellitus (Type 1)
  • Non-Insulin dependent diabetes mellitus (Type 2)

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter No. 1 Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2 Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Product
        • 2.1.1.2. Market Attractiveness Analysis, By Application
        • 2.1.1.3. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Human insulin Market, 2016 – 2028 (USD Billion)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3 COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4 Human insulin Market – Product Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Product, 2020 & 2028
    • 4.2. Drugs
      • 4.2.1. Market Size and Forecast, By Region (USD Billion)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Drug Delivery Devices
      • 4.3.1. Market Size and Forecast, By Region (USD Billion)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Human insulin Market – Application Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Application, 2020 & 2028
    • 5.2. Insulin dependent diabetes mellitus (Type 1)
      • 5.2.1. Market Size and Forecast, By Region (USD Billion)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Non-Insulin dependent diabetes mellitus (Type 2)
      • 5.3.1. Market Size and Forecast, By Region (USD Billion)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.1. Overview
      • 6.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 6.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Billion)
    • 6.2. North America
      • 6.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.2.2. North America Market Revenue, By Product, 2016 – 2028
      • 6.2.3. North America Market Revenue, By Application, 2016 – 2028
      • 6.2.5. U.S.
        • 6.2.5.1. U.S. Market Revenue, By Product, 2016 – 2028
        • 6.2.5.2. U.S. Market Revenue, By Application, 2016 – 2028
      • 6.2.6. Canada
        • 6.2.6.1. Canada Market Revenue, By Product, 2016 – 2028
        • 6.2.6.2. Canada Market Revenue, By Application, 2016 – 2028
      • 6.2.7. Mexico
        • 6.2.7.1. Mexico Market Revenue, By Product, 2016 – 2028
        • 6.2.7.2. Mexico Market Revenue, By Application, 2016 – 2028
    • 6.3. Europe
      • 6.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.3.2. Europe Market Revenue, By Product, 2016 – 2028
      • 6.3.3. Europe Market Revenue, By Application, 2016 – 2028
      • 6.3.5. Germany
        • 6.3.5.1. Germany Market Revenue, By Product, 2016 – 2028
        • 6.3.5.2. Germany Market Revenue, By Application, 2016 – 2028
      • 6.3.6. France
        • 6.3.6.1. France Market Revenue, By Product, 2016 – 2028
        • 6.3.6.2. France Market Revenue, By Application, 2016 – 2028
      • 6.3.7. U.K.
        • 6.3.7.1. U.K. Market Revenue, By Product, 2016 – 2028
        • 6.3.7.2. U.K. Market Revenue, By Application, 2016 – 2028
      • 6.3.8. Italy
        • 6.3.8.1. Italy Market Revenue, By Product, 2016 – 2028
        • 6.3.8.2. Italy Market Revenue, By Application, 2016 – 2028
      • 6.3.9. Spain
        • 6.3.9.1. Spain Market Revenue, By Product, 2016 – 2028
        • 6.3.9.2. Spain Market Revenue, By Application, 2016 – 2028
      • 6.3.10. Rest of Europe
        • 6.3.10.1. Rest of Europe Market Revenue, By Product, 2016 – 2028
        • 6.3.10.2. Rest of Europe Market Revenue, By Application, 2016 – 2028
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.4.2. Asia Pacific Market Revenue, By Product, 2016 – 2028
      • 6.4.3. Asia Pacific Market Revenue, By Application, 2016 – 2028
      • 6.4.5. China
        • 6.4.5.1. China Market Revenue, By Product, 2016 – 2028
        • 6.4.5.2. China Market Revenue, By Application, 2016 – 2028
      • 6.4.6. Japan
        • 6.4.6.1. Japan Market Revenue, By Product, 2016 – 2028
        • 6.4.6.2. Japan Market Revenue, By Application, 2016 – 2028
      • 6.4.7. India
        • 6.4.7.1. India Market Revenue, By Product, 2016 – 2028
        • 6.4.7.2. India Market Revenue, By Application, 2016 – 2028
      • 6.4.8. South Korea
        • 6.4.8.1. South Korea Market Revenue, By Product, 2016 – 2028
        • 6.4.8.2. South Korea Market Revenue, By Application, 2016 – 2028
      • 6.4.9. South-East Asia
        • 6.4.9.1. South-East Asia Market Revenue, By Product, 2016 – 2028
        • 6.4.9.2. South-East Asia Market Revenue, By Application, 2016 – 2028
      • 6.4.10. Rest of Asia Pacific
        • 6.4.10.1. Rest of Asia Pacific Market Revenue, By Product, 2016 – 2028
        • 6.4.10.2. Rest of Asia Pacific Market Revenue, By Application, 2016 – 2028
    • 6.5. Latin America
      • 6.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.5.2. Latin America Market Revenue, By Product, 2016 – 2028
      • 6.5.3. Latin America Market Revenue, By Application, 2016 – 2028
      • 6.5.5. Brazil
        • 6.5.5.1. Brazil Market Revenue, By Product, 2016 – 2028
        • 6.5.5.2. Brazil Market Revenue, By Application, 2016 – 2028
      • 6.5.6. Argentina
        • 6.5.6.1. Argentina Market Revenue, By Product, 2016 – 2028
        • 6.5.6.2. Argentina Market Revenue, By Application, 2016 – 2028
      • 6.5.7. Rest of Latin America
        • 6.5.7.1. Rest of Latin America Market Revenue, By Product, 2016 – 2028
        • 6.5.7.2. Rest of Latin America Market Revenue, By Application, 2016 – 2028
    • 6.6. The Middle-East and Africa
      • 6.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.6.2. The Middle-East and Africa Market Revenue, By Product, 2016 – 2028
      • 6.6.3. The Middle-East and Africa Market Revenue, By Application, 2016 – 2028
      • 6.6.5. GCC Countries
        • 6.6.5.1. GCC Countries Market Revenue, By Product, 2016 – 2028
        • 6.6.5.2. GCC Countries Market Revenue, By Application, 2016 – 2028
      • 6.6.6. South Africa
        • 6.6.6.1. South Africa Market Revenue, By Product, 2016 – 2028
        • 6.6.6.2. South Africa Market Revenue, By Application, 2016 – 2028
      • 6.6.7. Rest of Middle-East Africa
        • 6.6.7.1. Rest of Middle-East Africa Market Revenue, By Product, 2016 – 2028
        • 6.6.7.2. Rest of Middle-East Africa Market Revenue, By Application, 2016 – 2028
  • Chapter No. 7: Human insulin Market – Industry Analysis
    • 7.1. Introduction
    • 7.2. Market Drivers
      • 7.2.1. Driving Factor 1 Analysis
      • 7.2.2. Driving Factor 2 Analysis
    • 7.3. Market Restraints
      • 7.3.1. Restraining Factor Analysis
    • 7.4. Market Opportunities
      • 7.4.1. Market Opportunity Analysis
    • 7.5. Porter’s Five Forces Analysis
    • 7.6. PEST Analysis
    • 7.7. Regulatory Landscape
    • 7.8. Technulogy Landscape
    • 7.9. Regional Market Trends
      • 7.9.1. North America
      • 7.9.2. Europe
      • 7.9.3. Asia Pacific
      • 7.9.4. Latin America
      • 7.9.5. The Middle-East and Africa
    • 7.10. Pricing Analysis
    • 7.11. Value Chain Analysis
    • 7.12. Downstream Buyers
    • 7.13. Distributors/Traders List
  • Chapter No. 8: Competitive Landscape
    • 8.1. Company Market Share Analysis – 2019
      • 8.1.1. Global Human insulin Market: Company Market Share, 2019
      • 8.1.2. Global Human insulin Market, Company Market Revenue, 2016 – 2019 (USD Billion)
      • 8.1.3. Global Human insulin Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 8.1.4. Global Human insulin Market: Radar Determinant Chart, 2019
    • 8.2. Strategic Developments
      • 8.2.1. Acquisitions & Mergers
      • 8.2.2. New Product Launch
      • 8.2.3. Regional Expansion
    • 8.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 9: Company Profiles
    • 9.1. GlaxoSmithCline
      • 9.1.1. Company Overview
      • 9.1.2. Key Executives
      • 9.1.3. Product Portfulio
      • 9.1.4. Financial Overview
      • 9.1.5. Operating Business Segments
      • 9.1.6. Business Performance
      • 9.1.7. Recent Developments
    • 9.2. Eli Lilly
    • 9.3. Sanofi-Aventis
    • 9.4. Biocon
    • 9.5. Novo Nordisk
    • 9.6. Julphar
    • 9.7. Ypsomed AG
    • 9.8. SemBioSys
    • 9.9. Wockhardt
  • Chapter No. 10: Marketing Strategy Analysis
    • 10.1. Marketing Channel
    • 10.2. Direct Marketing
    • 10.3. Indirect Marketing
    • 10.4. Marketing Channel Development Trends
    • 10.5. Economic/Pulitical Environmental Change
  • Chapter No. 11: Research Methodulogy
    • 11.1. Research Methodulogy
    • 11.2. Phase I - Secondary Research
    • 11.3. Phase II - Data Modeling
      • 11.3.1. Company Share Analysis Model
      • 11.3.2. Revenue Based Modeling
    • 11.4. Phase III - Primary Research
    • 11.5. Research Limitations
      • 11.5.1. Assumptions

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Human Insulin market. Zion Research has collected and analyzed key data belong to the global Human Insulin market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Human Insulin across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Human Insulin industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Human Insulin market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Diabetes is described as a group of metabolic diseases in which the person has high blood glucose level than normal, either because insulin production is inadequate, or because the body's cells do not respond properly to insulin. Diabetes is a lifelong condition that is characterized by a raised blood glucose level. Diabetes is characterized into two types of diabetes: Insulin dependent diabetes mellitus (type 1) and Non-insulin dependent diabetes mellitus (type 2). Signs of diabetes include an increased sense of thirst, frequent urination, fatigue, weight and muscle loss, delayed wound healing and blurred vision. Human insulin therapy is utilized for the treatment of both type1 and type 2 diabetes mellitus.

The global rise in human insulin market is mainly due to the increase in diabetic disorder patient across the globe. Moreover, the factors those are responsible for increasing numbers of the diabetic population globally include sedentary lifestyles, obesity, the rise in geriatric populations and poor healthcare services. Furthermore, advanced technology like pen device, safety pen needles for efficient delivery of insulin is fueling the growth of the global human insulin market. However, production cost, manufacturing complexities and critical regulatory requirements for the approval of biotechnology derived products are factors which are expected to restraint the growth of the global human insulin market. Nonetheless, pipeline insulin products and untapped market of Asia Pacific and Africa are major opportunities for upcoming manufacturers of global human insulin markets.

Global Human Insulin Market

Based on products, the global human insulin market is segmented into two types: drugs and drug delivery devices. Drugs segment of human insulin market was contributing maximum market shares in 2015 followed by drug delivery devices. This segment is propelled by factors which include increasing in insulin dependent diabetic population, low cost, growing R&D for drug discovery, rising proportion of aging population in developed countries. In addition, increasing market accessibility of generic human insulin and rising government initiatives to support the development and commercialization of effective biosimilars are expected to fuel the growth of human insulin market over the forecast period 

Based on drug type, the global human insulin market is segmented into two types: Biosimilars and Human Insulin Biologics. In terms of revenue, biosimilars were the leading segment of human insulin market in 2015 followed by human Insulin biologics. Meanwhile, biosimilar will rise approximately at a steady CAGR of 7.34% during the forecast period.

Based on application, the global human insulin market is segmented into two types: type 1 diabetes and type 2 diabetes. Type 1 diabetes mellitus was the dominating segment in terms of revenue generated in 2015 followed by type 2 diabetes mellitus. Type 1 Diabetes Mellitus is an autoimmune disorder characterized by a lack of insulin formation in the body. About 100,000 new cases are diagnosed annually in North America. Human insulin serves as only medication for treating type 1 diabetes mellitus.

Key market players of human insulin market include Eli Lilly, GlaxoSmithCline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, and Wockhardt.


Frequently Asked Questions

The global Human insulin Market was valued at USD 33.7 Billion in 2020.

The global Human insulin Market is expected to reach USD 68.0 Billion by 2028, growing at a CAGR of 8.9% between 2021 to 2028.

Some of the key factors driving the global Human insulin Market growth are the rising market demand for human insulin analogs, increasing risk of diabetes, favorable medical reimbursements, and technological enactments.

North America has been leading the worldwide human insulin market and is anticipated to continue on the dominant position in the years to come.

Some of the major players of global Human insulin market GlaxoSmithCline, Eli Lilly, Sanofi-Aventis, Biocon, Novo Nordisk, Julphar, Ypsomed AG, SemBioSys, and Wockhardt, among others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social